Roche's schizophrenia drug meets Phase II study goals

11/10/2009 | Reuters

Roche Holding's RG1678 improved symptoms as well as personal and social functioning of schizophrenics in a Phase II trial, the company reported. The compound, which is co-developed with Chugai Pharmaceutical, was also well-tolerated at all doses.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX